loading
Precedente Chiudi:
$44.26
Aprire:
$44.12
Volume 24 ore:
1.45M
Relative Volume:
2.08
Capitalizzazione di mercato:
$2.45B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-16.09
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
+3.09%
1M Prestazione:
+21.99%
6M Prestazione:
-6.00%
1 anno Prestazione:
+15.99%
Intervallo 1D:
Value
$43.48
$46.67
Intervallo di 1 settimana:
Value
$42.40
$46.67
Portata 52W:
Value
$26.20
$63.50

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name
Nome
Apogee Therapeutics Inc
Name
Telefono
650-394-5230
Name
Indirizzo
221 CRESCENT ST., WALTHAM
Name
Dipendente
196
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
APGE's Discussions on Twitter

Confronta APGE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
APGE
Apogee Therapeutics Inc
44.32 2.45B 0 -146.66M -133.21M -2.7541
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-13 Iniziato Citigroup Buy
2024-11-25 Iniziato Canaccord Genuity Buy
2024-05-10 Iniziato BofA Securities Buy
2023-12-20 Iniziato BTIG Research Buy
2023-08-08 Iniziato Guggenheim Buy
2023-08-08 Iniziato Jefferies Buy
2023-08-08 Iniziato Stifel Buy
2023-08-08 Iniziato TD Cowen Outperform
2023-08-08 Iniziato Wedbush Outperform
Mostra tutto

Apogee Therapeutics Inc Borsa (APGE) Ultime notizie

pulisher
Jun 17, 2025

Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Contrasting argenx (NASDAQ:ARGX) and Apogee Therapeutics (NASDAQ:APGE) - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

APGE Stock Update: Apogee Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com

Jun 16, 2025
pulisher
Jun 16, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of “Buy” by Brokerages - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

Apogee Therapeutics stock maintains buy rating ahead of key trial data - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by California State Teachers Retirement System - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High? - sharewise

Jun 09, 2025
pulisher
Jun 06, 2025

Insider Sell: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Makes New $259,000 Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

Jun 06, 2025
pulisher
May 29, 2025

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

4,824 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by BNP Paribas Financial Markets - Defense World

May 29, 2025
pulisher
May 29, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Bank of America Corp DE - Defense World

May 29, 2025
pulisher
May 28, 2025

Millennium Management LLC Has $5.90 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 28, 2025
pulisher
May 27, 2025

(APGE) Investment Analysis and Advice - news.stocktradersdaily.com

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy rating, $35 target on Apogee Therapeutics stock - Investing.com

May 27, 2025
pulisher
May 27, 2025

D. E. Shaw & Co. Inc. Has $445,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 27, 2025
pulisher
May 26, 2025

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 26, 2025
pulisher
May 25, 2025

Deutsche Bank AG Boosts Stock Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 25, 2025
pulisher
May 25, 2025

Brokerages Set Apogee Therapeutics, Inc. (NASDAQ:APGE) Target Price at $94.60 - Defense World

May 25, 2025
pulisher
May 22, 2025

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet - MSN

May 22, 2025
pulisher
May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025
pulisher
May 17, 2025

How To Trade (APGE) - news.stocktradersdaily.com

May 17, 2025
pulisher
May 16, 2025

Northern Trust Corp Grows Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World

May 16, 2025
pulisher
May 15, 2025

Q1 Earnings Forecast for APGE Issued By Wedbush - Defense World

May 15, 2025
pulisher
May 15, 2025

Wedbush Equities Analysts Lift Earnings Estimates for APGE - Defense World

May 15, 2025
pulisher
May 13, 2025

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Apogee Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 13, 2025
pulisher
May 12, 2025

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class (APGE) - Seeking Alpha

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

BTIG maintains Apogee Therapeutics stock Buy rating, $100 target By Investing.com - Investing.com India

May 12, 2025
pulisher
May 12, 2025

BTIG maintains Apogee Therapeutics stock Buy rating, $100 target - Investing.com

May 12, 2025
pulisher
May 12, 2025

Why Is Apogee Therapeutics Stock Trading Higher On Monday? - Benzinga

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics reports positive results from asthma treatment trial - Seeking Alpha

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Resu - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Apogee (APGE) Sets Sights on Transformative Achievements in 2025 - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Q1 Loss Widens - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Reports Positive Phase 1b Trial Results - TipRanks

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Earnings Flash (APGE) Apogee Therapeutics Posts Q1 Net Loss $55.3M, vs. FactSet Est of $72.3M Loss - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Apogee Therapeutics Reports Positive Phase 1b Trial Results for APG808 in Asthma, Highlighting Durable FeNO Suppression and Potential for Extended Dosing Intervals - Nasdaq

May 12, 2025
pulisher
May 10, 2025

Apogee Therapeutics (APGE) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 10, 2025

Apogee Therapeutics chief medical officer sells shares totaling $97,418 By Investing.com - Investing.com Nigeria

May 10, 2025
pulisher
May 09, 2025

Apogee Therapeutics chief medical officer sells shares totaling $97,418 - Investing.com Australia

May 09, 2025

Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Apogee Therapeutics Inc Azioni (APGE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Dambkowski Carl
Chief Medical Officer
May 07 '25
Sale
35.75
2,725
97,419
244,448
Dambkowski Carl
Chief Medical Officer
Apr 02 '25
Sale
36.22
3,860
139,801
247,173
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):